Further mechanistic studies demonstrated that BZYQF can reduce glucose and lipid accumulation, enhance acetylcholine content, and improve pathological lesions and inflammation, as well as increasing the expression of signaling molecules—including PKA, IP3R, β1-AR, AQP5, CHRM3, and AMY1—in the salivary secretion pathway in the PG and SMG of T2DM rats. The gene discussed is ITPR1; the disease is type 2 diabetes mellitus.